News Releases | BioAtla, Inc

Date
8/28/24	BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
8/8/24	Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
8/1/24	BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
7/25/24	BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
7/23/24	BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
6/27/24	BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
5/29/24	BioAtla to Participate in the Jefferies Global Healthcare Conference
5/23/24	BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
5/14/24	BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
5/8/24	BioAtla to Participate in the Citizens JMP Life Sciences Conference